The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Biogen (I); Corcep; Fujifilm; Genzyme (I); Ipsen; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genentech (I); Genzyme (I); Ipsen; Novartis (I); Taiho Pharmaceutical; Teva (I)
Research Funding - Ambry Genetics (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst)
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly; Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Precision Oncology (Inst); Regeneron (Inst); Rgenix (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Vegenics (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Atif Abbas
Consulting or Advisory Role - Fujifilm
 
Catherine A. Wheeler
Leadership - Targovax
Stock and Other Ownership Interests - Targovax
Consulting or Advisory Role - CUE Biopharma; Fuji Pharma; Polyphor; Radius Health; Red Oak Medicines; Windmil
Travel, Accommodations, Expenses - Fuji Pharma; Targovax
 
Gary Maier
Consulting or Advisory Role - Fujifilm
 
Mary Johansen
Consulting or Advisory Role - Fujifilm
 
Paula Sedivy
No Relationships to Disclose
 
Ruth Ann Subach
Stock and Other Ownership Interests - Pfizer; Trevena
Consulting or Advisory Role - Fujifilm; Palladio Biosciences
Travel, Accommodations, Expenses - Fujifilm; Palladio Biosciences
 
Shiraj Sen
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - BioAtla (Inst); Exelixis (Inst); Jacobio (Inst); Loxo (Inst)
 
Suzanne Fields Jones
Consulting or Advisory Role - Clovis Oncology (Inst); Janssen (Inst); Novartis (Inst); Onyx (Inst); Teva (Inst); Vertex (Inst)
 
Tadaaki Ioroi
Employment - Fujifilm
Stock and Other Ownership Interests - Fujifilm
Travel, Accommodations, Expenses - Fujifilm
 
Takeshi Matsumoto
Employment - Fujifilm
Honoraria - Fujifilm
Research Funding - Fujifilm
Travel, Accommodations, Expenses - Fujifilm
 
Takeaki Suzuki
Employment - Fujifilm
 
Timothy Madden
Employment - Fujifilm; Fujifilm (I)
Stock and Other Ownership Interests - Reata Pharmaceuticals
Patents, Royalties, Other Intellectual Property - 60 patents held from my previous work as a faculty member at the University of Texas MD Anderson Cancer Center
Travel, Accommodations, Expenses - Fuji Pharma (I); Fujifilm
 
Erika Paige Hamilton
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Flatiron Health; Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ArQule (Inst); AstraZeneca (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fujifilm (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Kadmon (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); Mallinckrodt (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Oncothyreon (Inst); Pfizer (Inst); PharmaMar (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); TetraLogic Pharmaceuticals (Inst); Verastem (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro